KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.95

Granisetron transdermal delivery system versus palonosetron in the prevention of long-delayed nausea and vomiting: a phase III randomized trial.

Xiaojun Liu, Yanchun Meng, Yiqun Du, Yuxin Mu, Gang Li, Hengyu Li, Xiaoxiang Guan, Jian Zhang

Oncologist 31(3) oyag007

PMID41520166
PMCIDPMC12923111
DOI10.1093/oncolo/oyag007
发表日期2026-01-11
入排依据:The study is a Phase III randomized trial in oncology patients, but the primary endpoint is a categorical 'complete response rate' (vomiting and rescue medication use) during a specific time window, not a time-to-event outcome like OS or PFS. No Kaplan-Meier analysis or hazard ratio for a survival or progression endpoint is mentioned. Therefore, it does not meet the requirement for a time-to-event efficacy endpoint for this cohort.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Figure 1.:研究设计图;Figure 2.:非 KM 图;Figure 3.:森林图/亚组分析图;Figure 4.:森林图/亚组分析图;Figure 5.:森林图/亚组分析图;另有 1 张未列出。
摘要

摘要

BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) significantly impact the patients' quality of life. Whether the granisetron transdermal delivery system (GTDS) offers better protection than palonosetron against long-delayed (120-168 hours) CINV after highly or moderately emetogenic chemotherapy (HEC/MEC) had not been prospectively tested. METHODS: A multicenter, randomized clinical study was conducted in China. Patients scheduled to receive either HEC or MEC were randomly assigned (1:1) to GTDS or palonosetron, each in combination with a neurokinin-1 receptor antagonist (NK1-RA) and dexamethasone. The primary endpoint was the complete response (CR; no vomiting and no rescue medication) rate during the long-delayed phase (120-168 hours), stratified by HEC and MEC categories, to demonstrate the superiority of GTDS over palonosetron. RESULTS: Overall, 150 patients received either GTDS or palonosetron respectively. We found that the GTDS group demonstrated a significantly higher long-delayed CR rate (97.3%) than the palonosetron group (92%) (P = .04). This advantage was driven predominantly by the HEC subgroup (GTDS 97.5% vs palonosetron 90.8%, P = .028). No significant differences were observed between the groups for the acute (0-24 hours, 92.7% vs 90.0%; P = .412), delayed (24-120 hours, 80.0% vs 76.0%; P = .403), extended-delayed (24-168 hours, 80.7% vs 75.3%; P = .265), or overall (0-168 hours, 78.0% vs 74.0%; P = .417) phases. CONCLUSION: A GTDS-based triple antiemetic regimen can effectively control CINV associated with HEC or MEC. It provides a convenient alternative route for delivering granisetron for up to 7 days, with superior efficacy in controlling long-delayed CINV. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT04912271 (in-house ethic number: YBCSG-21-04).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Study design of clinical trial. This diagram illustrates the flow of patients from screening to final analysis, including randomization into GTDS and palonosetron arms, stratified by chemotherapy emetogenicity (HEC vs. MEC).
非 KM Figure
Figure 2.Complete response (CR) and complete control (CC) rates across time intervals in the overall population. (A) The CR (no vomiting and no rescue medication) rates during the acute (0-24 hours), delayed (24-120 hours), long-delayed (120-168 hours), extended delayed (24-168 hours), and overall (0-168 hours) phases in the cohort of all patients were calculated. (B) The CC (no emetic episodes, no rescue medication, and no more than mild nausea) rates during the acute (0-24 hours), delayed (24-120 hours), long-delayed (120-168 hours), extended delayed (24-168 hours), and overall (0-168 hours) phases in the cohort of all patients were calculated.
非 KM Figure
Figure 3.Complete response (CR) and complete control (CC) rates in the high emetogenic chemotherapy (HEC) subgroup. (A) The CR (no vomiting and no rescue medication) rates during the acute (0-24 hours), delayed (24-120 hours), long-delayed (120-168 hours), extended delayed (24-168 hours), and overall (0-168 hours) phases in the cohort of high emetic chemotherapy were calculated. (B) The CC (no emetic episodes, no rescue medication, and no more than mild nausea) rates during the acute (0-24 hours), delayed (24-120 hours), long-delayed (120-168 hours), extended delayed (24-168 hours), and overall (0-168 hours) phases in the cohort of high emetic chemotherapy were calculated.
非 KM Figure
Figure 4.Complete response (CR) and complete control (CC) rates in the moderate emetogenic chemotherapy (MEC) subgroup. (A) The CR (no vomiting and no rescue medication) rates during the acute (0-24 hours), delayed (24-120 hours), long-delayed (120-168 hours), extended delayed (24-168 hours), and overall (0-168 hours) phases in the cohort of moderate emetic chemotherapy were calculated. (B) The CC (no emetic episodes, no rescue medication, and no more than mild nausea) rates during the acute (0-24 hours), delayed (24-120 hours), long-delayed (120-168 hours), extended delayed (24-168 hours), and overall (0-168 hours) phases in the cohort of moderate emetic chemotherapy were calculated.
非 KM Figure
Figure 5.Daily complete response (CR) rates and patient satisfaction by chemotherapy subgroup. (A) Analysis of complete response rate in high emetic chemotherapy cohort on any day of follow-up. (B) Analysis of complete response rate in moderate emetic chemotherapy cohort on any day of follow-up. (C) Satisfaction with antiemetic therapy in high emetic chemotherapy cohort. (D) Satisfaction with antiemetic therapy in moderate emetic chemotherapy cohort. HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; OR, odds ratio.
非 KM Figure
Figure 6.Forest plot of subgroup analysis for long-delayed complete response (CR) (120-168 h).
非 KM Figure